CYTX and Astellas Pharma
the strategic equity agreement
to evaluate the potential of adipose derived stem and regenerative cells for the treatment of serious illnesses for which there is no fundamental treatment.
Astellas has purchased 1.43M unregistered shares of CYTX common stock at $7.00 per share for net proceeds to Cytori of $10M.
Referencing our blog, 12/7/10.